Asset Details
Do you wish to reserve the book?
Cellular Immune Response to COVID-19 and Potential Immune Modulators
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cellular Immune Response to COVID-19 and Potential Immune Modulators
Do you wish to request the book?
Cellular Immune Response to COVID-19 and Potential Immune Modulators
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cellular Immune Response to COVID-19 and Potential Immune Modulators
2021
Overview
Coronavirus disease 2019 (COVID-19) is a respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Droplets and contacts serve as the main route of transmission of SARS-CoV-2. The characteristic of the disease is rather heterogeneous, ranging from no symptoms to critical illness. The factors associated with the outcome of COVID-19 have not been completely characterized to date. Inspired by previous studies on the relevance of infectious diseases, viral and host factors related to clinical outcomes have been identified. The severity of COVID-19 is mainly related to host factors, especially cellular immune responses in patients. Patients with mild COVID-19 and improved patients with severe COVID-19 exhibit a normal immune response to effectively eliminate the virus. The immune response in patients with fatal severe COVID-19 includes three stages: normal or hypofunction, hyperactivation, and anergy. Eventually, the patients were unable to resist viral infection and died. Based on our understanding of the kinetics of immune responses during COVID-19, we suggest that type I interferon (IFN) could be administered to patients with severe COVID-19 in the hypofunctional stage, intravenous immunoglobulin (IVIG) and glucocorticoid therapy could be administered in the immune hyperactivation stage. In addition, low molecular weight heparin (LMWH) anticoagulation therapy and anti-infective therapy with antibiotics are recommended in the hyperactivation stage.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ COVID-19
/ Glucocorticoids - therapeutic use
/ Heparin
/ Heparin, Low-Molecular-Weight - therapeutic use
/ Humans
/ Immune response (cell-mediated)
/ Immunity, Cellular - drug effects
/ Immunoglobulins, Intravenous - therapeutic use
/ Immunologic Factors - therapeutic use
/ Interferon Type I - therapeutic use
/ Severe acute respiratory syndrome coronavirus 2
/ Viruses
